18 August 2021 - - The immediate impacts of COVID-19 are increasingly documented and understood, however, the long-term consequences of infection and recovery are still unknown. To address these questions, US-based My Own Med, Inc is playing an important role in support of the new NIH IMPACC (IMmunoPhenotyping Assessment in a COVID-19 Cohort) study, the company said.

The IMPACC study will use the MyOwnMed ECOS Mobile app, a comprehensive digital remote monitoring tool, to capture direct-from-patient, real-world evidence and will access important data and custom analytics through the MyOwnMed ECOS Portal.

IMPACC, sponsored by the National Institute of Allergy and Infectious Diseases, will enroll up to 2,000 COVID-19-infected, post-hospitalization patients at 10 leading medical centers across the United States, seeking to learn how their immune systems respond over time.

The MyOwnMed ECOS Platform will serve as an ongoing way of tracking patient-reported physical, mental, and social health recovery statistics.

Moving forward, the ECOS Mobile app, containing a COVID-19 symptom tracker will be utilized over the course of the one-year follow-up study as a patient-centric remote digital tool to monitor and address any persistent COVID-like symptoms.

The patient-reported data will be used to correlate with over 200,000 collected samples to measure immune system responses aimed to help understand and guide treatments for COVID-19 recovery.

MyOwnMed will be working with Dr. Charles Cairns, MD, FACEP, FAAEM, FAHA, Walter H. and Leonor Annenberg Dean and senior vice president of Medical Affairs at Drexel University's College of Medicine Dean of Drexel University College of Medicine and Dr. Albert Ozonoff and his team at the National IMPACC Clinical and Data Coordinating Center located at Boston Children's Hospital.

The MyOwnMed Platform is a highly configurable platform for distributed health data collection and analyses for clinicians and researchers.